Aigeboya Completes New Round of Hundred-Million-Yuan Financing with Life Capital as Financial Advisor

VCBeat learned at the earliest opportunity that the leading provider of comprehensive separation and purification solutions in ChinaSuzhou Aijie Boya Bioelectronics Technology Co., Ltd. (hereinafter referred to as: Aijie Boya)Gaining Capital Favor Again,Announces Completion of New Round of Financing in the Hundreds of Millions. This round of financing was led byHuada Win-Win FundandDetong CapitalInvestment: Some existing shareholders continue to make additional investments,Life CapitalServed as the financial advisor for this round.

The funds raised in this round will continue to be used for the industrial chain layout and dual-brand promotion of Aijie Boya, accelerating the establishment of Aijie Boya’s comprehensive drug separation and purification solutions as well as its automated platform for clinical mass spectrometry sample preparation.

Suzhou Aijie Boya Bioelectronics Technology Co., Ltd. centers on chromatography technology, with innovation in separation materials and precision fluid automation control as its two key pillars. Its main products include instruments, equipment, and separation media for the separation and purification of organic compounds, with a particular focus on peptide drugs, nucleic acid drugs, and antibody-drug conjugate (ADC) therapies. The company provides next-generation high-end technical equipment and solutions for downstream biomanufacturing processes such as extraction, separation, and purification, while also offering advanced tools and technologies to meet the separation, analysis, and purification needs of life science laboratories. Headquartered in Nano City within the Suzhou Industrial Park, the company operates under the dual brands of Aijie Boya and Boyun Biology.

Dr. Qunjie Wang, Founder of Aijie BoyaStatement: We extend our sincere gratitude, as always, to both new and old friends in the investment community for their affirmation and support. China’s upstream life sciences industry is advancing rapidly toward high-quality, intelligent development. In line with Agelab’s corporate mission—to lead industry “connections” through technology and drive pharmaceutical “intelligent manufacturing” through innovation—we hope that Agelab’s comprehensive drug separation and purification solutions (including Bonnasil preparative chromatography resins, SmartPurifier laboratory-to-Seepure industrial-scale separation and purification liquid chromatography systems, process development services, etc.) and automated clinical mass spectrometry sample pretreatment solutions (including Bonnacats-MS/MA magnetic extraction materials, AUTO M96/AUTO M32 fully automated sample pretreatment systems, Air plate P96 positive-pressure solid-phase extraction instruments, Air plate N96 nitrogen blow-down concentrators, etc.) will provide stronger momentum for achieving a breakthrough in the “localization” of the domestic biopharmaceutical supply chain, thereby facilitating the integration of biopharmaceutical processes and engineering into the global arena. Currently, Agelab is rapidly advancing the localization of key materials for focus areas such as nucleic acid drugs, peptides, and antibody-drug conjugates (ADCs). In the longer term, the company will expand into broader application fields based on core technologies related to personalized extraction automation and industrial separation and purification automation, thereby achieving more original innovations.

Mr. Zhang Junhong, Board Secretary and CFO of Suzhou Aijie Boya Bioelectronics Technology Co., Ltd.Statement: It is a great honor to join this family during the company’s phase of accumulating strength for significant breakthroughs. Throughout this round of financing, I have deeply felt the capital market’s firm support for the localization and intelligent transformation of the bio-manufacturing and life sciences industries. With the backing of the capital market, Suzhou Aijie Boya Bioelectronics Technology Co., Ltd. will become a leader in providing comprehensive solutions for separation and purification.

Mr. Liu Yu, Founding Partner of Huada Win WinStatement: In recent years, Huada Win Win has actively responded to the 14th Five-Year Plan for the Bioeconomy by supporting the establishment of the "Bioeconomy Think Tank" (Huagu Research Institute), co-hosting multiple sessions of the "Bioeconomy 50 Forum," and spearheading the initiation of the "Biomanufacturing Industry Alliance" to build a biotechnology industry ecosystem. In the field of industrial investment, the company focuses on the track of hard-core biotechnologies, strategically laying out its portfolio around key links in the entire biomanufacturing value chain—specifically "production, detection, and separation"—and prioritizing hard-tech projects with independent intellectual property rights and core technologies. As a member of the "Biomanufacturing Industry Alliance," Suzhou Aijie Boya Bioelectronics Technology Co., Ltd. holds a leading position in the field of silica-based fillers for process separation in biomanufacturing. Led by Dr. Wang, its R&D team has built a full-chain technology system ranging from matrix synthesis to surface modification, leveraging over 20 years of expertise in bioseparation media. Its related products have been successfully applied in the large-scale production of various biologics. We believe that with the accelerated industrial development of peptide drugs, nucleic acid drugs, and antibody-drug conjugates (ADCs), and with the expanding global influence of Chinese manufacturing, Aijie Boya is poised to become an international leading enterprise mastering core bottleneck technologies within the biomanufacturing industry chain.

Ms. Yu Jiani, Partner at Detong CapitalDetong Capital stated: "The healthcare industry has long been a key focus area for Detong Capital. The chromatography resin business undertaken by Suzhou Aijie Boya Bioelectronics Technology Co., Ltd. is a critical link in the pharmaceutical supply chain and represents the 'pick-and-shovel' strategy that we have always valued. Leveraging its team's nearly four decades of accumulated industrialization experience, the company is one of the few domestic enterprises to master core technologies. It has independently developed industrial chromatography resins characterized by high purity and high yield, which will significantly enhance industry efficiency and drive the purity of domestic active pharmaceutical ingredients (APIs) to new heights. With leading product performance, the company's offerings have garnered strong recognition from numerous customers shortly after their market launch. As an industry leader, the company is well-positioned to benefit from the rapid growth driven by the surge in downstream peptide drugs, particularly GLP-1 analogs. We are delighted to participate in and support the company's growth at this stage."

Huada Win-Win, as a venture capital firm backed by the BGI Group’s industrial ecosystem, combines the dual advantages of Corporate Venture Capital (CVC) and traditional Venture Capital (VC), leveraging both industrial resources and flexible decision-making mechanisms. Advocating the investment philosophy of “R&D-driven investment,” the firm insists on mapping industry landscapes and proactively investing along the industrial chain. Focusing on the bio-manufacturing sector, it provides full-stage investment coverage for high-quality projects in the bio-economy, including areas such as hardcore biological technologies, biomaterials, and biopharmaceuticals. Committed to becoming a leading innovative investment management institution in the bio-economy, Huada Win-Win facilitates resource sharing and mutually beneficial development among industrial partners, fund investors, and portfolio companies. The firm currently manages assets exceeding RMB 2 billion and has cumulatively invested in over 30 healthcare projects. Historically, the team has invested in nearly 80 projects, with close to 20 achieving Initial Public Offerings (IPOs), representing an IPO rate of approximately 25%. For consecutive years, Huada Win-Win has received honorary awards from prestigious institutions such as Zero2IPO Research Center, China Venture, Financing China, the Fund of Funds Research Center, and VCBeat.

DT Capital is a leading professional private equity fund management firm in China, with a long-term focus on the healthcare, advanced manufacturing, and next-generation information technology sectors. The firm has accumulated extensive experience and delivered consistent, stable performance. Its RMB-denominated funds under management currently exceed RMB 10 billion. Founding Partners Mr. Shao Jun and Mr. Tian Lixin have worked together for over 20 years since 2000. DT Capital has successfully helped nearly 30 portfolio companies list on major stock exchanges and become leaders in their respective niche industries. The firm has been consistently recognized as a top-tier investment institution in China, and its key partners have been repeatedly honored as China’s Best Investors.

Since its establishment in 2017, Life Capital has been a boutique investment bank deeply rooted in the life sciences and broader healthcare sectors. Upholding the mission of “Empowering Leaders in the Healthcare Industry,” we provide strategic and capital support to industry changemakers. By leveraging strategy-driven approaches, capital services, and industrial ecosystem enablement, we foster innovative development within the healthcare industry. Our services span private equity financing, mergers and acquisitions, asset management, and industrial strategic advisory. We have accumulated profound expertise in niche sectors including innovative drugs, new infrastructure for biopharmaceuticals, biotechnology, synthetic biology, medical devices, digital health, consumer healthcare, and agricultural health. To date, we have successfully completed over 60 financing transactions, with a total financing volume reaching RMB 30 billion. Life Capital is committed to continuously refining its capabilities and resources. Guided by value creation, we provide high-quality empowerment throughout the entire lifecycle of healthcare enterprises, utilizing diversified professional services to help businesses break through commercial constraints and drive deeper commercial and social value.